This article is more than 5 years old. Information may no longer be current.
Glycemic control, anti-hyperlipidemic agents may prevent diabetic macular edema progression in some patients
Click Here to Manage Email Alerts
Anti-hyperlipidemic agents could play a role in halting macular edema in some patients with diabetes and hypertension, a study of patients taking those agents found.
“These data indicated that intense glycemic control and administration of anti-hyperlipidemic agents may be effective to prevent the progression of macular edema in diabetic patients with hypertension,”Noriko Miyamoto, MD, and colleagues said in a poster study at the World Ophthalmology Congress.
The researchers presented results of 84 patients with diabetes, retinopathy and hypertension who were taking anti-hypertensive agents. In the study, multiple linear regression evaluated the correlation of factors including sex, age, HbA1c, diabetic nephropathy, number of anti-hypertensive agents, insulin and systemic anti-coagulants with clinically significant macular edema.
“Significant factors for macular edema were HbA1c and anti-hyperlipidemic agents, but no correlation was found between diabetic macular edema and anti-hypertensive agents and other factors in diabetic patients with hypertension,” the researchers said.
Follow
EndocrineToday.com on Twitter.